Patient Perceptions of Using the OmniPod System Compared with Conventional Insulin Pumps in Young Adults with Type 1 Diabetes

Lebenthal, Yael; Lazar, Liora; Benzaquen, Hadassa; Shalitin, Shlomit; Phillip, Moshe

doi:10.1089/dia.2011.0228

Cited by 27 publications

(40 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,11 The present study evaluates glycemic outcomes in a large cohort of patients with type 1 diabetes previously treated with MDI or CSII therapy after initiating Omnipod therapy.…”

mentioning

confidence: 99%

Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion

Layne

Parkin²,

Zisser

2016

J Diabetes Sci Technol

View full text Add to dashboard Cite

Background: Continuous subcutaneous insulin infusion (CSII) treatment with a tubeless patch pump has not been previously evaluated in a large cohort of patients. Methods: This multisite, retrospective study evaluated glycemic control in patients with type 1 diabetes (n = 873) after 3 months treatment the Omnipod® insulin management system (Insulet Corporation, Billerica, MA) compared to prior treatment with multiple daily injections (MDI) (78.1%) or CSII (21.9%). The primary outcome was change in HbA1c from baseline at 3 months post–Omnipod treatment initiation. Secondary outcomes included shifts in HbA1c to target levels, change in total daily dose (TDD) of insulin and in the frequency and severity of hypoglycemic episodes. Results: HbA1c was significantly improved at 3 months post–Omnipod treatment for the total population (mean ± SD): −0.6% ± 1.3 ( P < .001). HbA1c was also significantly lower compared to MDI: −0.3% ± 1.3, −0.4% ± 1.4, −0.8% ± 1.3 and −0.6% ± 1.3 ( P = .002 to P < .001) and CSII: −0.3% ± 0.8, −1.1% ± 1.6 ( P < .01), −0.4% ± 1.1 ( P < .001), and −0.5% ± 1.1 ( P < .001) for pediatric, adolescent, adult, and total populations, respectively. There was a 37.9% change increase in the proportion of patients ≥18 years and a 39.3% change increase in those <18 years achieving ADA treatment targets ( P = .004 to P < .001). There was a 16.4% change decrease in TDD of insulin at 3 months for the total population ( P < .001). The frequency of self-reported hypoglycemia decreased significantly ( P < .001) by 1.0 ± 2.4 episodes per week. Conclusions: Treatment with the Omnipod insulin management system was associated with clinically meaningful and statistically significant improvement in glycemic control, reduction in daily insulin requirement and reduction in the frequency and severity of hypoglycemic episodes.

show abstract

“…10,11 The present study evaluates glycemic outcomes in a large cohort of patients with type 1 diabetes previously treated with MDI or CSII therapy after initiating Omnipod therapy.…”

mentioning

confidence: 99%

Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion

Layne

Parkin²,

Zisser

2016

J Diabetes Sci Technol

View full text Add to dashboard Cite

show abstract

“…Continuity, which refers to aspects of interventions that facilitate contact between young adults and the diabetes service, was the most prominent theme across studies, occurring in 13 of the 18 studies reviewed . Continuity within diabetes services or in the context of a study was implemented by ensuring that participants met, or were in contact with, the same diabetes team members at each clinic or by a research visit , or by assigning one care coordinator . Hernandez et al .…”

Section: Resultsmentioning

confidence: 99%

“…Five studies reported on patient satisfaction with the intervention with only one study using a validated measure . Only one of the four Health Service Delivery intervention studies provided feedback from participants on the intervention , with all of those in the structured transition group reporting a good experience of structured transition, whereas 70% of the control group reported a poor/bad experience of the unstructured transition process.…”

Section: Resultsmentioning

confidence: 99%

“…Of 1700 abstracts screened, 18 studies published between 1991 and 2013 met the inclusion criteria, as illustrated in Fig. 1 [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. Most were published by research groups in North America and Canada (n = 10), five were from northwest Europe, two from Israel and one from Australia.…”

Section: Resultsmentioning

confidence: 99%

“…Diabetes devices were tested in four studies [33][34][35][36]. Two focused on insulin pumps [33,34], one on an insulin pen [35], and one on a blood glucose monitor [36].…”

Section: Diabetes Devices (N = 4)mentioning

confidence: 99%

See 2 more Smart Citations

A systematic review of interventions to improve outcomes for young adults with Type 1 diabetes

et al. 2016

View full text Add to dashboard Cite

BackgroundMany young adults with Type 1 diabetes experience poor outcomes. The aim of this systematic review was to synthesize the evidence regarding the effectiveness of interventions aimed at improving clinical, behavioural or psychosocial outcomes for young adults with Type 1 diabetes.MethodsElectronic databases were searched. Any intervention studies related to education, support, behaviour change or health service organizational change for young adults aged between 15‐30 years with Type 1 diabetes were included. A narrative synthesis of all studies was undertaken due to the large degree of heterogeneity between studies.ResultsEighteen studies (of a possible 1700) were selected and categorized: Health Services Delivery (n = 4), Group Education and Peer Support (n = 6), Digital Platforms (n = 4) and Diabetes Devices (n = 4). Study designs included one randomized controlled trial, three retrospective studies, seven feasibility/acceptability studies and eight studies with a pre/post design. Continuity, support, education and tailoring of interventions to young adults were the most common themes across studies. HbA1c was the most frequently measured outcome, but only 5 of 12 studies that measured it showed a significant improvement.ConclusionBased on the heterogeneity among the studies, the effectiveness of interventions on clinical, behavioural and psychosocial outcomes among young adults is inconclusive. This review has highlighted a lack of high‐quality, well‐designed interventions, aimed at improving health outcomes for young adults with Type 1 diabetes.

show abstract

Device‐Enabled Drug Infusion Therapies

Hildebrand

2015

Drug‐Device Combinations for Chronic Diseases

View full text Add to dashboard Cite

Patient Perceptions of Using the OmniPod System Compared with Conventional Insulin Pumps in Young Adults with Type 1 Diabetes

Abstract: The OmniPod system was well received by young adults with type 1 diabetes experienced with conventional CSII.

Cited by 27 publications

References 9 publications

Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion

Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion

A systematic review of interventions to improve outcomes for young adults with Type 1 diabetes

Device‐Enabled Drug Infusion Therapies

Contact Info

Product

Resources

About